Source:http://linkedlifedata.com/resource/pubmed/id/12602913
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2003-2-26
|
| pubmed:abstractText |
Crucial event in the metastasis of cancer cells is the secretion of matrix metalloproteinases (MMPs), which are responsible for the degradation of extracellular matrix (ECM). Among them, matrix metalloproteinase-2 (MMP-2) is a gelatinase, which degrades basement membrane type-IV collagen. Immunohistochemistry was performed to detect MMP-2 protein in 135 infiltrative breast carcinomas. MMP-2 was studied along with clinicopathological parameters (tumor size, histological type, nuclear and histological grade, stage, lymph node status, ER, and PR), patients' survival and tissue inhibitor metalloproteinase-2 (TIMP-2), Ki-67, and p53 proteins. MMP-2 immunoreactivity was detected in the cytoplasm in cancer cells in 102 (75.6%) and in both tumor and tumor stromal cells in 37 (27.4%) of 135 cases respectively. MMP-2 reactivity in cancer cells displayed a statistically significant association with tumor size > 2 cm (p = 0.022). In tumor stromal cells a strong parallel association was observed between the expression of MMP-2 and TIMP-2 (p = 0.015), while an inverse correlation was found between MMP-2 and both Ki-67 and p53 (p = 0.033 and p = 0.034 respectively). In the subgroup with negative lymph nodes MMP-2 was also inversely associated with p53 in cancer cells (p = 0.045). Finally a statistically significant association was revealed using Kaplan-Meier and Cox's proportional hazard regression model between the MMP-2/TIMP-2 phenotype and patients' better survival (p = 0.021). Our results point out the strong relation between MMP-2 and TIMP-2 and the effect of the MMP-2/TIMP-2 phenotype in the patients' overall survival. The inverse correlation between MMP-2 and both Ki-67 and p53 can be explained by the potential inhibition of MMP-2 by TIMP-2. These results suggest the necessity of further investigation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0167-6806
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
77
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
145-55
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12602913-Adult,
pubmed-meshheading:12602913-Aged,
pubmed-meshheading:12602913-Aged, 80 and over,
pubmed-meshheading:12602913-Breast Neoplasms,
pubmed-meshheading:12602913-Carcinoma, Ductal, Breast,
pubmed-meshheading:12602913-Carcinoma, Lobular,
pubmed-meshheading:12602913-Female,
pubmed-meshheading:12602913-Humans,
pubmed-meshheading:12602913-Immunohistochemistry,
pubmed-meshheading:12602913-Ki-67 Antigen,
pubmed-meshheading:12602913-Matrix Metalloproteinase 2,
pubmed-meshheading:12602913-Middle Aged,
pubmed-meshheading:12602913-Neoplasm Invasiveness,
pubmed-meshheading:12602913-Neoplasm Metastasis,
pubmed-meshheading:12602913-Neoplasm Staging,
pubmed-meshheading:12602913-Phenotype,
pubmed-meshheading:12602913-Survival Analysis,
pubmed-meshheading:12602913-Tissue Inhibitor of Metalloproteinase-2,
pubmed-meshheading:12602913-Tumor Suppressor Protein p53
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival.
|
| pubmed:affiliation |
Department of Pathology, Medical School, The National and Kapodistrian University of Athens, Athens, Greece. lnakopou@cc.uoa.gr
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|